The Obesity-Drug Revolution: An Era That Targets “Biology,” Not “Willpower”

An era is coming where the pain of eating—while stressing, blaming yourself, and spiraling at year-end and New Year—fades away, and you can feel food as something beautiful again.

1) The standard for how we view obesity has changed: it’s not “personality,” it’s a “signaling system”

Hello. I’ll calmly unpack the story of obesity medications.

In the past, weight management was often treated like a “willpower game.” But the recent direction is clear. Obesity is increasingly understood not as something easily explained by “mindset,” but as the result of biological signals exchanged among the brain, gut, pancreas, and adipose tissue. And treatment is evolving toward “pulling those signals into view and holding them steady.”

There’s a reason this shift matters especially during year-end and New Year. What many people struggle with isn’t the food itself—it’s the self-blame loop that follows eating. When the signaling system stabilizes, the speed of that loop can slow down. Moving from a “fight you must endure” to a state that’s “regulated with less noise.”

2) By what mechanism do changes occur in our bodies?

From here, I’ll organize the key mechanisms in an explanatory way.

(1) GLP-1 class: increases satiety and reduces the noise of hunger

GLP-1 receptor agonists are designed to mimic a natural hormone, suppress appetite, and strengthen satiety. At the same time, they’re often discussed alongside a related axis: slowing gastric emptying (how fast the stomach empties) and helping stabilize blood glucose more steadily.

In short, it’s not a drug that shouts “Don’t eat!”—it’s closer to a brake that catches hunger before it overheats.

GLP-1 (Glucagon-Like Peptide-1)
In one line: A hormone that sends the “I’m full” signal to the brain

What does it do?

• Naturally secreted from the gut when you eat

• Sends satiety signals to the brain

• Slows gastric emptying, so you feel full faster and stay full longer

• Insulin secretion ↑ → helps regulate blood sugar

Why is it important?

• The central backbone of today’s obesity drugs

• The most “natural” mechanism for “making you eat less”

(2) The GIP axis: creates synergy with GLP-1 and also interacts directly with fat cells

GIP receptor activity is described as synergizing with GLP-1 in the brain. At the same time, it’s also discussed as directly interacting with adipocytes (fat cells) to inhibit fat accumulation. Keywords like stimulating thermogenesis often follow along.

Why does this matter? Because it opens room to touch not only “appetite,” but also the levers of storage, consumption, and metabolism.

GIP (Glucose-dependent Insulinotropic Polypeptide)
In one line: GLP-1’s partner—and a hormone that regulates energy storage and usage

What does it do?

• Promotes insulin secretion when blood sugar rises

• Acts on fat cells, muscle, and the brain

• Related to the efficiency of energy use

Point

• Previously misunderstood as a “hormone that makes you gain weight”

• Recent research shows weight-loss synergy when used together with GLP-1

3) A ‘map of obesity-drug products’: once you see generations and platforms, it’s organized in one shot

To understand products, it’s faster to look through platforms (mechanistic axes) and generations (direction of evolution) than to debate “this company’s drug is good/bad.”

A. GLP-1 monotherapy: the ‘main rail’ of modern obesity drugs

Semaglutide-based therapies are commonly grouped together as “stars.” Names like Wegovy, Saxenda, and Ozempic are often mentioned together as representative examples.

(Here, Saxenda is a liraglutide-based drug and is often mentioned as an “earlier runner” in generational terms.)

Liraglutide (Liraglutide)
In one line: The original GLP-1 obesity drug, a 1st-generation star

What kind of drug is it?

• A medication form of the GLP-1 hormone

• Appetite ↓

• Satiety ↑

• Blood glucose stabilization

Features

• Once-daily injection

• Clear weight-loss effect, but weaker than newer drugs

Meaning

• The first drug to prove “obesity can be regulated by hormones”

• The direct ancestor of today’s semaglutide and tirzepatide

• Simply put: the “iPhone 1st generation” of obesity drugs

B. Dual class (GLP-1 + GIP): the axis where Eli Lilly ‘sped up the game’

The representative of the dual axis is tirzepatide, and the products/brands Zepbound and Mounjaro move together with it.

Tirzepatide (Tirzepatide)
In one line: A “dual player” that stimulates GLP-1 + GIP at the same time

Why is it innovative?

• Regulates two hormones at once, not just one

• Appetite ↓ + blood glucose ↓ + fat-metabolism efficiency ↑

• In clinical trials, greater weight loss than semaglutide

If I had to compare it

• Semaglutide = an ace pitcher

• Tirzepatide = a two-way player who pitches + hits ⚾

And if you want to see the flow naturally, you can view Eli Lilly as the key actor that pushed this dual platform the hardest—commercially and clinically.

To put it more intuitively:

• If Novo Nordisk is the leader that refined the GLP-1 single axis to the highest level,

• Eli Lilly is the axis that took the competition up a notch by adding GIP to GLP-1 and increasing the “control levers” via a dual strategy.

C. The oral (pill) race: a battlefield that opens the “door to diffusion”

Injections are powerful, but for some people, starting itself is a barrier. That’s why oral (pill) GLP-1 is continually emphasized. In the materials, orforglipron and oral semaglutide are mentioned as “pills that are approaching injection-level efficacy.”

The key here isn’t just convenience. Pills can change the breadth of the market (accessibility). In other words, the very “route by which they are widely used in real medical settings” could change.

D. Next-gen (triple / long-acting): a direction that touches ‘maintenance’ and ‘real-world feasibility’

The next round isn’t only about “more.” Realistically, it becomes about longer and more stable.

• Retatrutide is mentioned as a triple agonist targeting GLP-1 / GIP / glucagon, with phrasing like “unprecedented results” attached to Phase 2.

• In the global competitive landscape, names like Eli Lilly – Retatrutide, Amgen – MariTide, Viking – VK2735, Roche appear lined up in one row.

• Another key point: on the time axis, the launches of Wegovy (2021) and Zepbound (2023) are summarized as opening a “golden era.”

That is, the materials also carry the idea that “the game changed” starting around 2021–2023.

E. Precision targeting (specific patient groups): ‘not all obesity is the same obesity’

Treatments like Setmelanotide, which focus on specific genetic obesity, are mentioned as examples of “precision medicine.”

Setmelanotide
In one line: A “precision-target drug” for extremely rare genetic obesity

Features

• GLP-1 class ❌

• Directly regulates the brain’s appetite switch pathway called MC4R

• For patients with congenital appetite overdrive

Point

• Not for general obesity treatment

• A case that shows “not all obesity has the same cause”

This axis is important in a different way than “mass-market therapies.” Because it moves away from bundling obesity into one simplified category—and toward separating causes and patient groups.

4) Competitive landscape: the ‘Big 2’ build the board, and challengers shake the rules

If you summarize this market in the simplest and most accurate way, it looks like this:

✅ Big 2: Novo Nordisk vs Eli Lilly

• Novo Nordisk: the axis running through Wegovy, Saxenda, Ozempic, Amycretin

• Eli Lilly: the axis running through Zepbound, Mounjaro, Retatrutide

And challengers are sprinting toward them. In the materials, Amgen (MariTide), Viking (VK2735), Roche, etc. appear grouped as “Emerging Contenders.”

Here, the competitive question is usually not “who’s more famous,” but moves to:

1. Form factor and usability: pill vs injection, and can the dosing interval be extended?

2. Long-term maintenance data: can it last for a long time without dropping off? (This is huge in real clinics.)

3. Supply and manufacturing power: when demand explodes, the ability to “produce” becomes the edge

4. Safety and label management: with strong drugs, if the safety frame shakes, the entire market can swing

5) An industry research lens: the core checklist when watching this field

Rather than knowing a lot of product names, the flow becomes much clearer if you hold onto the checklist below.

Check 1) From “behavior” to “biology”—is the paradigm shifting?

In the materials, the sentence “the focus shifts from behavior to biology” is embedded as a core message.

That single line is meaningful. It signals that this market is not a short-term fad, but can be structured as chronic-disease management.

Check 2) The oral war isn’t a “convenience” war—it’s a “diffusion speed” war

This is why orforglipron and oral semaglutide are mentioned in the direction of “a pill approaching injection-level efficacy.”

Orforglipron
In one line: Next-gen GLP-1 without injections—taken as a pill

Features

• Non-peptide based

• Refrigeration ❌, injections ❌

• Favorable for mass production and distribution

Meaning

• An acceleration button for mainstreaming and commercialization of obesity drugs

Oral Semaglutide
In one line: A version of semaglutide made into a “take-by-mouth” medicine

Why was it hard?

• GLP-1 is normally broken down in the stomach

• A special absorption technology succeeded in crossing the barrier

Meaning

• Breaks the fixed idea that “obesity treatment = injections”

• Medication adherence ↑

Pills can change the patient experience and lower the threshold for prescribing, distribution, and access.

Check 3) Next-gen (triple / long-acting) is closer to “lasting longer” than “losing more”

While triple agonists (e.g., Retatrutide) are described as “unprecedented results,”

Retatrutide (Retatrutide)
(I mentioned it earlier, but let’s organize it properly here.)

In one line: The most powerful candidate among obesity drugs currently in development

What kind of drug is it?

• GLP-1

• GIP

• Glucagon
  👉 A “triple action” that regulates three hormones at the same time

How the effect is structured

• Appetite ↓ (GLP-1)

• Blood glucose stabilization + fat-metabolism efficiency ↑ (GIP)

• Energy expenditure ↑ (Glucagon)

Key differentiator

• Stops at “eat less” ❌

• Includes “burn more” ✅

If I compare it: Dieting + metabolic booster + fuel-burning engine

The market increasingly shifts the question to “how long can it be maintained, and how realistically can it be sustained?”

Check 4) Safety isn’t a “side effect list”—it’s “sustainability”

In the materials, practical issues like pancreatitis, gallbladder problems, and delayed gastric emptying (gastroparesis / reduced gastric emptying) are organized together.

In other words, as powerful efficacy rises, the core becomes: how safely, and how long, can we go together?

6) One more time, in metaphors (a version that ‘sticks’ in memory)

The explanation is enough—so I’ll lock it into your head with metaphors.

• The brain is a notification center.
  If hunger notifications are too loud and too frequent, your day becomes notification hell.
  The GLP-1 axis lowers the volume of those alerts and makes the satiety alerts clearer.

• The stomach is a logistics center.
  If shipping out (gastric emptying) is too fast, reorders (snacks) keep coming in.
  Slowing gastric emptying means the “satisfaction” from the existing inventory lasts longer.

• GIP is an auxiliary engine—or an extra lever.
  GLP-1 alone can work, but adding GIP increases the control levers.
  That’s why explanations follow about brain synergy and interactions with fat cells (like inhibiting accumulation).

• Oral pills are lowering the doorstep.
  Even if the function is great, if the door is heavy, fewer people enter.
  Pills lower that doorstep and can change the number of people who “come in” in the first place.

Closing

Let me summarize.

The obesity-drug revolution is a shift in the center of gravity—from “a story of enduring with willpower” to “a story of regulating biological signals.”

And at the center of that change are Novo Nordisk’s GLP-1 rail and Eli Lilly’s dual platform,

with the next rounds—oral, triple, and long-acting—unfolding rapidly.

At year-end and New Year, no longer letting stress and self-blame amplify the pain of eating—returning food to an experience you can feel as “beautiful.”
That may be the biggest change this era is expecting.